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CC BY-NC-ND license (http://creativeAbstract Objective: To systematically evaluate the effectiveness and safety of Chinese
herbal medicine (CHM) plus nucleotide analogues (NAs) for treating compensated HBV-
related cirrhosis, the early stage of cirrhosis.
Methods: PubMed, Cochrane library, China Network Knowledge Infrastructure Database
(CNKI), Chinese Scientific Journals Database (VIP), Wan Fang Database and Sino-Med Database
were searched. Randomized controlled trials (RCTs) and quasi-RCTs comparing NAs and NAs
plus CHM therapy on patients with compensated HBV-related cirrhosis were included. Two re-
viewers independently extracted information and assessed the methodological quality of the
trials. Different CHM herbal formulas used in the trials were considered. Primary meta-
analysis was conducted when there were at least two trials comparing the same CHM formula.
Results: Forty-five trials comprising 3497 participants were included. The quality of most of
the trials was moderate or low. Twenty-six herbal formulations were identified. A meta-
analysis was conducted for compound Biejia Ruangan (FFBJ), Dahuang Zhechong (DHZC),
and Fuzheng Huayu (FZHY). The results of the subgroup analysis showed a beneficial effect
of FFBJ plus entecavir (ETV), and DHZC plus adefovir dipivoxil (ADV) on hyaluronic acid
(HA); FFBJ plus ADV on laminin (LN); and FZHY plus ADV on HA, LN, and precollagen type III
(PC-III). The results from other studies suggested significant benefits of CHM plus NAs compared
with NAs alone, except those on albumin (ALB). None of the trials evaluated the quality of life0@163.com (T. Wang), yutong_fei@163.com (Y. Fei).
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12 T. Li et al.or reported severe adverse events.
Conclusions: A positive effect was found for FFBJ plus ETV, DHZC plus ADV, and FZHY plus ADV
on HA; FZHY plus ADV and FFBJ plus ADV on LN; and FZHY plus ADV on PCIII compared with the
effects of NAs used alone.
ª 2015 Beijing University of Chinese Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Cirrhosis is regarded as the result of chronic liver disease
and is characterized by the replacement of liver tissue with
fibrous scar tissue as well as the histological development
of regenerative nodules leading to portal hypertension and
end-stage liver disease.1 Approximately 350 million people
worldwide are chronically infected with hepatitis B virus
(HBV)2 and > 82% of the Chinese population suffering from
cirrhosis have had a history of HBV infection.3 The natural
incidence of cirrhosis ranges from 8% to 20% at 5 years in
patients with hepatitis B e antigen (HBeAg)epositive
chronic hepatitis B.4,5 The 5-year cumulative incidence of
hepatic cell carcinoma is w20% in patients with compen-
sated cirrhosis6,7 and their 5-year survival rate is w80%e
85%.8
The mainstream medications for treating compensated
HBV-related cirrhosis are interferons (IFNs) and nucleotide
analogues (NAs). However, the practice guidelines of the
American Association for the Study of Liver Diseases suggest
that patients with compensated cirrhosis should receive
long-term treatment with NAs because of the risk of he-
patic decompensation associated with IFN-a-related flares
of hepatitis,9 even if IFNs can reduce liver fibrosis by
lowering hepatic stellate cells (HSC)5 and even though NAs
have some side effects, such as fatigue, anorexia, an initial
influenza-like illness, and even serious renal toxicity.9,10
Together with the use of antiviral drugs, many tradi-
tional Chinese physicians and those who integrate Chinese
and western medicine have combined CHM with NAs in
treating cirrhosis,11e13 especially in treating compensated
HBV-related cirrhosis.14e16 However, there has been no
relevant systematic review to assess the effectiveness and
safety of CHM plus NAs in treating the disease.Methods
Search strategy
PubMed, Cochrane Library, and four major Chinese elec-
tronic databases (China Network Knowledge Infrastructure
Database, CNKI; Chinese Scientific Journals Database, VIP;
Wan Fang Database and Sino-Med Database) were searched
from their inception to October 9, 2014. Unpublished post-
graduate theses listed in Chinese databases and trials in
Clinicaltrials (www.clinicaltrials.gov) and the Chinese clin-
ical trial registry (www.chictr.org/cn/) were also searched.
The search terms were used individually or in combina-
tion, and comprised “cirrhosis”, “hepatitis B”,“compensat*”, “traditional Chinese medicine”, “TCM”,
“Chinese herbal medicine”, “herbal medicine”, “herb*”,
and “random*” in English or Chinese. We attempted to
identify all relevant trials regardless of language or publi-
cation status (published, unpublished, in press, or in
progress).
Selection criteria
The inclusion criteria for the study were as follows:
1) RCTs and quasi-RCTs, regardless of blinding.
2) Participants with compensated HBV-related cirrhosis as
diagnosed by validated diagnostic criteria.
3) Therapy with CHM plus NAs versus NAs alone. Conven-
tional treatments were allowed as long as they were
used in both groups. Neither group who used other
complementary and alternative medicine treatments,
such as acupuncture or moxibustion were allowed
regardless of the method of administration. There were
no restrictions on frequency, dose, or duration.
4) The primary outcome was liver biopsy. The secondary
outcomes were liver fibrosis biomarkers [hyaluronic acid
(HA), laminin (LN), precollagen type III (PC-III), and
type-IV collagen (IV-C)], liver function biomarkers
[alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), albumin (ALB), and total bilirubin (TBiL)],
liver stiffness, quality of life, and adverse events.Study selection and data extraction
Two reviewers (TTL, XYW) independently assessed all
potentially relevant studies for inclusion using a screening
criteria table. The reasons for excluding studies were
stated and any disagreements were resolved through dis-
cussion. The data on basic participant information, in-
terventions, duration, outcomes, and adverse events were
extracted.
Trial quality assessment
Two reviewers (TTL, XLX) independently assessed the risk
of bias according to the following seven points: sequence
generation, allocation concealment, blinding of partici-
pants and personnel, blinding of outcome assessment,
incomplete outcome data, selective outcome report, and
other bias. For each of these components, a judgment was
made regarding the risk of bias as being high, low, or
Chinese herbal medicine combined with nucleotide 13unclear based on guidance from the “Cochrane Handbook
for Systematic Reviews of Interventions”.17 Any disagree-
ments were resolved through discussion.
Data analyses
Data were analyzed using RevMan 5.3 (Cochrane Informatics
& Knowledge Management Department, London, UK).
Dichotomous data were expressed as a risk ratio (RR) and
continuous outcomes as the weighted mean difference
(WMD) and included their 95% confidence intervals (CI). If the
data required were not reported, the corresponding author
was contacted for the absent data. Because of the unavoid-
able intervention heterogeneity, the random effects model
was used topool data in this systematic reviewwhen I2< 75%.
When I2 75%, data were not pooled. Subgroup analysis was
conducted under the following conditions:
1) studies used the same CHM and NAs;
2) the estimated effects of trials with low risk and high risk
of bias needed to be compared.
Results
Forty-five trials with 3497 participants were included in the
study. All trials were conducted in China and published in
Chinese. The detailed characteristics of the included trials
are provided in Table 1. The mean sample size was 78
(range: 38e320) and the mean duration of treatment was 10
months (range: 3.0e24 months). CHM was classified into 26
major types according to the formula composition, and three
major types of NAs, lamivudine (LAM), entecavir (ETV), and
adefovir dipivoxil (ADV), were identified. Apart from these
NAs, conventional drugs used were glutathione, polyene
phosphatidylcholine, creatinine, and vitamins. There were
four comparisons made among the drugs as follows: CHM
plus LAM versus LAM,20,23,31,32,41,42 CHM plus ETV versus
ETV,14,16,25,27,33,35,36,41,45,47,48,50,52,54e56 CHM plus ADV versus
ADV,15,18,19,21,22,24,26,28e30,34,37,38,40,44,46,49,51,58,59 and CHM
plus multiple NAs versus multiple NAs.43,53,57 Fig. 1 shows the
search process.
Assessment of methodological quality
Among the 45 trials, six25,26,45,55e57 used the random num-
ber table, one33 used SPSS 20.0 (IBM Corporation, Armonk,
NY, USA), and eight20e22,27,34,35,49,53 generated the random
sequence using a rule based on date of admission or on
hospital or clinic record number. The remaining trials sim-
ply mentioned “randomization” and did not provide the
specific method of random sequence generation. Two tri-
als33,57 used sequentially numbered opaque sealed enve-
lopes; 12 trials18,20e22,25,27,34,35,45,49,53,55 used non-random
allocation schedule. The methods of concealment used in
the remaining trials were not described. None of the trials
reported any information on drop-out cases; however, ac-
cording to the number of participants randomized and
analyzed, 12 trials14,15,23,25,27,31,39,41,46,47,50,55 had no
missing outcome data. The study protocols were not
available. Apart from the three trials41,43,56 that reported a
liver biopsy, none mentioned biopsy or any otherinformation on the quality of life, clinical symptoms, or the
progression of the disease (Fig. 2 and Additional File 1).Effects of the interventions
Liver biopsy
Three studies reported the results of a liver biopsy.41,43,56
Data could not be pooled because different measures
were used to assess the outcomes. From Table 2, we find
that the intervention group treated with the combined
treatment showed better effects in terms of controlling
inflammation, Knodell HAI score, and HSC counts.
Biomarkers for liver fibrosis
As shown in Table 3, three trials23,31,41 with 282 participants
compared CHM plus LAM with LAM alone and all showed that
the combined treatment significantly reduced the levels of
HA, LN, PC-III, and IV-C.
Fourteen trials14,16,25,27,33,35,36,45,47,48,50,54e56 compared
CHM plus ETV with ETV alone and showed that the com-
bined treatment reduced the levels of
HA,16,25,27,33,35,45,47,54,56 LN,14,16,25,27,33,35,45,48,54e56 and IV-
C.14,25,35,36,45,48,50,54,56 Ten trials14,16,25,27,36,48,50,54e56 sug-
gested that the combined treatment had obvious advan-
tages in reducing the levels of PC-III. Two trials showed no
statistical differences in reducing the levels of HA,36,50
LN,36,47 or IV-C33,47 and four trials33,35,45,47 showed no sta-
tistical difference in reducing the levels of PC-III. For IV-C,
one trial27 suggested that ETV alone was better than ETV
plus CHM. The meta-analysis was done because the three
studies14,48,55 used the same CHM and NAs and the results
supported that FFBJ plus ETV had a significant advantage in
reducing the levels of HA (WMD 30.76; 95% CI, 39.04,
22.47; P < .00001; I2 Z 9%) (Fig. 3 and Table 4).
As shown in Figs. 4e6 and Table 5, 16 tri-
als15,19,21,22,24,26,30,34,37,38,40,46,49,51,58,59 that compared
CHM plus ADV versus ADV alone were included in this study.
Eleven trials suggested that there was no statistical dif-
ference between the two groups in reducing HA,37
LN,38,40,51 PC-III,15,24,38,46,58 or IV-C.22,34,51 One trial21
showed that ADV alone could be more effective in
reducing the levels of LN. A meta-analysis was performed
according to CHM classifications and the methodological
quality of the trials. DHZC plus ADV versus ADV alone19,51
(pooled WMD 22.11; 95% CI, 42.99, 1.24; P Z .04;
I2 Z 0%) and FZHY plus ADV versus ADV alone30,34 (pooled
WMD-89.03; 95% CI, 112.18, 65.88; P < .00001; I2Z 33%)
suggested that the combined treatment had more advan-
tages in reducing HA. FFBJ plus ADV versus ADV
alone15,22,24,46 (pooled WMD-12.22; 95% CI, 19.84, 4.61;
PZ .002; I2Z 0%) and FZHY plus ADV versus ADV alone30,34
(pooled WMD-20.54; 95% CI, 35.62, 5.47; P Z .008;
I2 Z 56%) showed that the combined treatment was better
than ADV alone in reducing the levels of LN. FZHY plus ADV
versus ADV alone30,34 (pooled WMD-37.76; 95% CI, 47.47,
28.06; P < .00001; I2 Z 0%) showed that the combined
treatment had an obvious advantage in reducing the levels
of PC-III. As for comparing CHM plus multiple NAs versus
multiple NAs alone, two trials43,53 showed that the com-
bined treatment could reduce the levels of HA, PC-III, and
IV-C, while one trial53 gave the same results as the above,
Table 1 Characteristics of the included trials.
Study ID Sample
size (I:C)
Age Intervention
group; Disease
course (years)
Control group;
Disease
course (years)
Course of
treatment
(months)
Outcomes Adverse
events
Dai, 201114 68 (34:34) Avg 46.2
(32e66)
FFBJþETV
NR
ETV
NR
12 ALT/AST/TBiL;
HA/LN/IV-C/PCIII
NR
Dai, 201315 66 (33:33) NR FFBJþADV
NR
ADV
NR
12 ALT/AST/TBiL;
HA/LN/IV-C/PCIII
N
Ding, 201216 50 (26:24) NR BSHYþETV
NR
ETV
NR
3 ALT/AST;
HA/LN/PCIII
N
Fu, 200818 68 (37:31) NR HLSGþADV
NR
ADV
NR
6 ALT/AST/TBiL NR
Gui, 201219 71 (37:34) NR DHZCþADV
NR
ADV
NR
6 ALT/AST/TBiL;
HA/LN/PCIII
NR
Hao, 200820 55 (28:27) Avg
41.4  6.2
(30e48)
DHZCþLAM
2e10
LAM
3e10
12 ALT/ALB/TBiL Y,
Stools
frequency
increased
Hu, 201121 70 (35:35) Avg
42.4  10.2
(18e56)
HLSGþADV
NR
ADV
NR
12 HA/LN/IV-C Y,
nausea
and
vomiting
caused
by ADV
Hu, 201222 50 (25:25) Avg 46
(30e62)
FFBJþADV
NR
ADV
NR
12 ALT/ALB/TBiL;
HA/LN/IV-C/PCIII
NR
HuZB, 201123 120 (60:60) 42.5 FFBJþLAM
11.5
LAM
11.8
6 ALT/AST/TBiL;
HA/LN/IV-C/PCIII
NR
Jin, 201024 60 (30:30) 25e59 FFBJþADV
2e20
ADV
3e23
12 ALT/AST;
HA/LN/IV-C/PCIII
N
Lang, 201325 152 (76:76) Avg
46  10
(41e59)
FFDSþETV
2e17
ETV
3e16
6 ALT/AST/TBiL;
HA/LN/IV-C/PCIII
NR
Li, 201226 48 (25:23) Avg
40.53  6.54
(21e62)
YiGJþADV
Avg 6.8  2.32
(0.5e18)
ADV
Avg 6.92  2.45
(0.5e18)
12 HA/LN/IV-C/PCIII NR
Li, 201327 65 (33:32) 46.75  9.83 XiXSþETV
9.31  7.85
ETV
10.12  7.37
6 HA/LN/IV-C/PCIII NR
Liao, 200928 53 (28:25) 28e49 FFBJþADV
2e9
ADV
3e10
12 ALT/ALB/TBiL NR
Liu, 201329 128 (66:62) 31e58 DHZCþADV
2e15
ADV
2e13a
12 ALT/AST/ALB/TBiL Y,
diarrhea
and
epigastric
discomfort
LiuMD, 201330 80 (40:40) 31.2  9.7 FZHYþADV
5.7  2.6
ADV
5.6  2.5
6.5 ALT/AST/TBiL;
HA/LN/IV-C/PCIII
NR
LiuYJ, 201331 97 (52:45) NR QiGaþLAM
NR
LAM
NR
12 ALT/AST/ALB/TBiL;
HA/LN/IV-C/PCIII
NR
Lu, 200732 53 (28:25) 26e47 QiGaþLAM
2e10
LAM
3e10
12 ALT/ALB/TBiL NR
Lv, 201233 40 (20:20) 43.7  8.52 RJHYþETV
9.24  2.38
ETV
9.84  1.75
6 ALT/AST/ALB/TBiL;
HA/LN/IV-C/PCIII
N
Pan, 200934 93 (48:45) 41  1.58 FZHYþADV
11  1.2
ADV
11.3  2.3
6 HA/LN/IV-C/PCIII NR
Pei, 201235 58 (29:29) 43.3  11.7 FZHYþETV
NR
ETV
NR
12 ALT/AST/ALB/TBiL;
HA/LN/IV-C/PCIII
Y, Mild
epigastric
discomfort
Peng, 201436 50 (25:25) 42.3  11.3 GLXDþETV
NR
ETV
NR
12 ALT/AST/ALB/TBiL;
HA/LN/IV-C/PCIII
NR
14 T. Li et al.
Table 1 (continued )
Study ID Sample
size (I:C)
Age Intervention
group; Disease
course (years)
Control group;
Disease
course (years)
Course of
treatment
(months)
Outcomes Adverse
events
Qian, 201137 89 (46:43) 25e61 YQHYRJþADV
8e19
ADV
9e20
18 ALT/AST;
HA/LN/IV-C/PCIII
NR
Qin, 201238 60 (30:30) 25e59 FZRGþADV
2e20
ADV
3e23
12 ALT/AST/TBiL;
HA/LN/IV-C/PCIII
N
Shen, 201439 72 (42:30) Avg 39.2
(19e58)
LWWLþETV
Avg 9.8 (4e16)
ETV
Avg
10.1 (4e15)
12 ALT/AST N
Si, 200940 58 (28:30) 34e56 RuGaþADV
2e9
ADV
3e7
12 ALT/ALB/TBiL;
HA/LN/IV-C/PCIII
Y,
Upper
abdominal
discomfort,
nausea and
vomiting
caused
by ADV
Song, 200841 65 (33:32) Avg 42.5  12.6
(28e51)
Marine Capsules
þLAM
NR
LAM
NR
12 Liver biopsy;
ALT/ALB/TBiL;
HA/LN/IV-C/PCIII
N
Su, 200942 53 (28:25) 26e47 HLSGþLAM
2e10
LAM
3e10
12 ALT/ALB/TBiL NR
Wang, 200943 97 (49:48) NR ALHXþLAM
þADVþETV
NR
LAM
þADVþETV
NR
24 Liver biopsy;
ALT/ALB/TBiL;
HA/LN/IV-C/PCIII
NR
Wang, 201044 132 (67:65) 24e51 DHZCþADV
2e12
ADV
2e11
12 ALT/AST/ALB/TBiL NR
Wang, 201245 60 (30:30) NR YQPXXQþETV
NR
ETV
NR
6 HA/LN/IV-C/PCIII;
liver stiffness
NR
Wei, 201046 44 (22:22) NR FFBJþADV
NR
ADV
NR
12 ALT/AST/TBiL;
HA/LN/IV-C/PCIII
NR
Xiao, 201447 60 (30:30) 28e70 RGWJþETV
NR
ETV
NR
6 HA/LN/IV-C/PCIII N
Xie, 201046 80 (40:40) Avg 41.8
(24e60)
HYYGþADV
Avg 12.5 (5e18)
ADV
Avg 12.1
(4e17)
6 ALT/AST/TBiL;
HA/LN/IV-C
NR
Yan, 201448 56 (29:27) Avg 44.5
(27e64)
FFBJþETV
Avg 16.9 (3e32)
ETV
Avg 17.8
(2e30)
12 ALT/ALB/TBiL;
HA/LN/IV-C/PCIII;
liver stiffness
N
Yang, 201149 63 (33:30) NR JWXYþADV
NR
ADV
NR
12 ALT/AST/TBiL;
HA/LN/PCIII
NR
Yuan, 201350 50 (25:25) NR SGJPHXþETV
NR
ETV
NR
6 ALT/AST/TBiL;
HA/PCIII/IV-C
N
Zhang, 200851 45 (23:22) Avg 35.6
(28e47)
DHZCþADV
NR
ADV
NR
12 HA/LN/IV-C/PCIII Y, mild
diarrhea,
headache
Zhang, 201252 220 (112:108) Avg 41.46
(30e48)
FFBJþETV
2e10
ETV
3e10
6 ALT/ALB/TBiL NR
Zhang, 201353 60 (30:30) Avg 45
(29e61)
DaYeþLAMþADV
Avg 4.5 (0.5e10)
LAMþADV
Avg 4.6
(0.5e11)
12 HA/LN/IV-C/PCIII NR
ZhangFM, 201254 38 (20:18) 43  8 CHM Decoction
þETV
3.1  2.3
ETV
2.9  2
6 ALT/AST/ALB/TBiL;
HA/LN/IV-C/PCIII
N
ZhangW, 201355 64 (32:32) Avg 45.5
(42e70)
FFBJþETV
Avg 15(10e18)
ETV
Avg 16
(8e20)
6 ALT/AST/TBiL;
HA/LN/PCIII
NR
(continued on next page)
Chinese herbal medicine combined with nucleotide 15
Table 1 (continued )
Study ID Sample
size (I:C)
Age Intervention
group; Disease
course (years)
Control group;
Disease
course (years)
Course of
treatment
(months)
Outcomes Adverse
events
Zheng, 201256 320 (160:160) 17e56 RGHXþETV
0.6e22
ETV
0.6e24
12 Liver biopsy;
ALT/ALB/TBiL;
HA/LN/IV-C/PCIII
N
Zhou, 201357 56 (28:28) 40.96  9.53 FFBJþADV/ETV
/ADVþETV
5.12  2.23
ADV/ETV
/ADVþETV
5.37  2.08
3 Liver stiffness NR
Zhu, 201258 60 (30:30) 35.2  9.6 WJBFþDHZC
þADV
4.5
ADV
5.2
12 ALT/AST/TBiL;
HA/LN/IV-C/PCIII
NR
I: Intervention group; G: Control group; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALB: Albumin; TBiL: Total
bilirubin; HA: Hyaluronic acid; LN: Laminin; PC-III: Precollagen type III; IV-C: Type IV collagen; LAM: Lamivudine; ADV: Adefovir dipivoxil;
ETV: Entecavir; FFBJ: Compound Biejia Ruangan Tablets; BSHY: Bushen Huayu Decoction; HLSG: Heluo Shugan Capsule; DHZC:
Dahuangzhechong Pill; FFDS: Compound Danshen Dripping Pills; YiGJ: Yiguanjian Decoction; XiXS: Xiaoxian Pulvis; FZHY: Fuzheng Huayu
Capsule; QiGa: Qianggan Capsule; RJHY: Ruanjian Huayu Decoction; GLXD: Ganlu Xiaodu Pill; YQHYRJ: Yiqi Huayu Ruanjian Decoction;
FZRG: Fuzheng Ruangan Pill; LWWL: Liuwei Wuling tablets; RuGa: Ruangan pill; ALHX: Anluo Huaxian Pill; YQPXXQ: Yiqi Poxue Xingqi
Decoction; RGWJ: Ruangan Wenjing Paste; HYYG: Huayu Yigan Capsule; JWXY: Jiawei Xiaoyao Capsule; SGJPHX: Shugan Jianpi Huoxue
Decoction; DaYe: Danye Capsule; RGHX: Ruangan Huaxian Capsule; WJBF: Wuji Baifen Wan; NR: No report; N: No; Y: Yes.
16 T. Li et al.and the other showed no statistical difference in reducing
the levels of LN.
Biomarkers for liver function
Thirty-three trials reported the outcome of identifying liver
function biomarkers. Compared to NAs alone,
ALT,16,18e20,22,25,28,31e33,35,36,39e43,46,48e50,52,54e56,58,59
AST,16,18,19,25,29,31,33,35,37,39,44,49,50,54,55,58,59 and
TBiL18,20,22,28,29,31,32,35,36,41,42,44,48e50,52,54e56,58,59 could be
significantly reduced by treating with CHM plus NAs; how-
ever, for ALB, only seven trials31,40,41,43,52,54,56 suggested
that the combined treatment was better than NAs alone,
while the others showed no statistical difference between
the two groups in increasing the levels of ALB (Additional
File 2).
Liver stiffness
Three trials45,48,57 reported liver stiffness. Although these
trials used different drugs and treatment courses, a meta-
analysis was done to determine the difference between
CHM plus NAs and NAs alone in decreasing liver stiffness,
which is a new index by which to assess liver fibrosis in
patients with cirrhosis. Finally, the results showed that the
combined group had more significantly statistical differ-
ences than the group with NA treatment alone (random,
pooled WMD 2.85; 95% CI, 3.91, 1.79; P < .00001;
I2 Z 0%).
Quality of life
None of the trials reported on the quality of life of the
participants.
Adverse events
Six trials20,21,29,35,40,51 described the adverse effects of the
treatments in detail. Among them, two21,40 trials reported
upper abdominal discomfort, nausea, and vomiting andsuggested that they were related to NAs, and four20,29,35,51
trials reported mild epigastric discomfort, mild diarrhea,
and headache. Twelve trials15,16,24,33,38,39,41,47,48,50,54,56
reported no adverse effects; 27 tri-
als14,18,19,22,23,25e28,30e32,34,36,37,42e46,49,52,53,55,57e59 had no
information on adverse events.
Publication bias
We did not conduct funnel plots because there were less
than 10 studies in each and every meta-analysis.
Discussion
Summary of the main results
From the results of the meta-analysis, FFBJ plus ETV, DHZC
plus ADV, and FZHY plus ADV were more effective on HA
than ETV or ADV alone. FZHY plus ADV and FFBJ plus ADV
had obvious advantages in reducing LN. FZHY plus ADV was
superior to ADV alone on PC-III. The results from the other
single trials showed potential benefits of CHM plus LAM,
CHM plus ETV, CHM plus ADV, and CHM plus multiple NAs to
improving HA, LN, PC-III, IV-C, ALT, AST, TBiL, and liver
stiffness; improvement in ALB level was the only exception.
The quality of life of the participants and severe adverse
events were not reported.
Quality of the evidence
There is most likely performance bias because none of the
45 trials included those of blinded participants and
personnel. Considering this, all trials were defined as “high
risk of bias”. For detection bias, the overall quality of the
45 included trials was defined as “low risk of bias” because
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(n = 49 ): Clinicaltrials (n=11), 
ChiCTR (n=38)
Records aŌer duplicates removed
(n =4204 )
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(n =4204 )
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interest (n=3)
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Figure 1 Procedure for searching, screening, and selecting literature with the numbers of articles at each stage.
Notes: CNKI, China National Knowledge Infrastructure; VIP, Chinese Scientific Journal Database; CBM, Chinese Biomedical data-
base; ChiCTR, Chinese Clinical Trial Registry.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
Figure 2 Risk of bias graph.
Author judgments on each risk-of-bias item presented as percentages across all included studies.
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Table 2 Qualitative synthesis of liver biopsy.
Study ID Group n Results RR (95%CI) or MD (95%CI)
Song, 200841 Intervention group 10 G3(n Z 0), G2(n Z 1), G1(n Z 4), G0(n Z 5) 4.00 [0.55, 29.10]
Control group 10 G3(n Z 0), G2(n Z 2), G1(n Z 6), G0(n Z 2)
Wang, 200943 Intervention group 14 Knodell HAI reduced 3e4 scores;
Control group 12 Knodell HAI reduced 2 scores;
Zheng, 201256 Intervention group 56 Activated HSC 16.95  11.59 3.53 [8.51, 1.45]
Control group 44 Activated HSC 20.48  13.35
Intervention group 56 Apoptotic activated HSC 10.78  5.72 2.66 [0.95, 4.37]
Control group 44 Apoptotic activated HSC 8.12  2.78
G: Grade; HAI: Histological activity index; HSC: Hepatic stellate cell.
Table 3 The original data and mean difference of the comparison, CHM plus LAM versus LAM, examining the effect on HA, LN,
PC-III, IV-C.
Study or Subgroup CHMþLAM LAM Mean Difference [95%CI]
Mean SD Total Mean SD Total
HA
HuZB, 201123 115.6 79.5 60 198.7 78.6 60 83.10 [111.39, 54.81]
LiuYJ, 201331 185.3 21.35 52 245.6 39.78 45 60.30 [73.29, 47.31]
Song, 200841 112.8 46.5 33 186.5 56.5 32 73.70 [98.90, 48.50]
LN
HuZB, 201123 86.6 33.1 60 159.3 32.3 60 72.70 [84.40, 61.00]
LiuYJ, 201331 109.9 23.86 52 158 29.78 45 48.10 [58.95, 37.25]
Song, 200841 107.5 45.7 33 142.7 65.6 32 35.20 [62.76, 7.64]
PC-III
HuZB, 201123 110.6 28.8 60 186.3 30.5 60 75.70 [86.31, 65.09]
LiuYJ, 201331 110.5 12.94 52 167.4 18.97 45 56.90 [63.46, 50.34]
Song, 200841 105.6 53.8 33 163 76.6 32 57.40 [89.67, 25.13]
IV-C
HuZB, 201123 72.5 25.8 60 165.7 26.6 60 93.20 [102.58, 83.82]
LiuYJ, 201331 75.39 29.67 52 112.5 19.78 45 37.11 [47.03, 27.19]
Song, 200841 86.5 45.7 33 126.7 56.6 32 40.20 [65.25, 15.15]
HA: Hyaluronic acid; LN: Laminin; PC-III: Precollagen type III; IV-C: Type IV collagen; LAM: Lamivudine; CHM: Chinese herbal medicine.
18 T. Li et al.the outcome measurement was not likely to be influenced
by lack of blinding.Potential bias/limitations
First, potential selection bias was unavoidable because the
pertinent English databases, such as AMED and EMBASE,
were not searched, all of the included trials were retrievedStudy or Subgroup
Dai2011
Yan2014
ZhangW2013
Total (95% CI)
Heterogeneity: Tau² = 9.45; Chi² = 2.20, df = 2 (P = .33); I² = 9%
Test for overall effect: Z = 7.27 (P < .00001)
Mean
70.2
147.57
185.46
SD
11.7
75.12
38.61
Total
34
29
32
95
Mean
98.8
169.18
229.56
SD
17.2
85.45
43.28
Total
34
27
32
93
Weight
80.6%
3.8%
15.6%
100.0%
-
-
-3
FFBJ+ETV ETV
Figure 3 The effect on HA of FFBJ plus ETV with ETV.
Notes: HA, hyaluronic acid; ETV, entecavir; FFBJ, compound Biejiafrom Chinese literature, and some negative previously un-
published studies might have been included. Second, we
did not conduct meta-analysis in which different types of
CHM formulations were combined as one general inter-
vention. The results of the meta-analysis for the general
picture of CHM treatment were not available from our re-
view. In addition, most included trials had the following
issues that contributed to the limited methodological
quality:IV, Random, 95% CI
28.60 [-35.59, -21.61]
-21.61 [-63.88, 20.66]
44.10 [-64.20, -24.00]
0.76 [-39.04, -22.47]
Mean Difference Mean Difference
IV, Random, 95% CI
-50 -25 0 25 50
Favours [FFBJ+ETV] Favours [ETV]
Ruangan tablets.
Table 4 The original data and mean difference of the comparison, CHM plus ETV versus ETV, examining the effect on HA, LN,
PC-III, IV-C.
Study or Subgroup CHMþETV CHMþETV Mean difference
95%CIMean SD Total Mean SD Total
HA
Ding, 201216 117.3 21.5 26 153.6 23.2 24 36.30 [48.73, 23.87]
Lang, 201325 73 23 76 221 59 76 148.00 [162.24, 133.76]
Li, 201327 73.67 23.46 33 221.49 59.42 32 147.82 [169.91, 125.73]
Lv, 201233 97.6 27.26 20 139.34 60.94 20 41.74 [71.00, 12.48]
Pei, 201235 138.5 34.5 29 239.7 52.8 29 101.20 [124.16, 78.24]
Peng, 201436 115.27 62.81 25 144.5 82.9 25 29.23 [70.00, 11.54]
Wang, 201245 104.54 89.15 30 165.55 105.21 30 61.01 [110.36, 11.66]
Xiao, 201447 296.5 92.4 30 356.3 112.5 30 59.80 [111.89, 7.71]
Yuan, 201350 145.16 44.48 25 152.8 39.09 25 7.64 [30.85, 15.57]
ZhangFM, 201254 85.61 27.43 20 125.45 20.78 18 39.84 [55.22, 24.46]
Zheng, 201256 108.48 26.8 160 123.22 27.9 160 14.74 [20.73, 8.75]
LN
Dai, 201114 39.6 7.1 34 53.8 11.2 34 14.20 [18.66, 9.74]
Ding, 201216 98.6 24.7 26 139.6 26.4 24 41.00 [55.20, 26.80]
Lang, 201325 91 24 76 119 32 76 28.00 [36.99, 19.01]
Li, 201327 91.25 24.37 33 119.43 32.87 32 28.18 [42.28, 14.08]
Lv, 201233 35.64 6.53 20 63.92 5.49 20 28.28 [32.02, 24.54]
Pei, 201235 39.8 7.3 29 53.9 10.6 29 14.10 [18.78, 9.42]
Peng, 201436 79.6 45.58 25 110.43 64.3 25 30.83 [61.73, 0.07]
Wang, 201245 87.47 59.53 30 142.8 16.9 30 55.33 [77.47, 33.19]
Xiao, 201447 135.5 56.3 30 145.8 74.2 30 10.30 [43.63, 23.03]
Yan, 201448 102.87 43.45 29 136.98 33.24 27 34.11 [54.29, 13.93]
ZhangFM, 201254 103.31 31.52 20 146.42 21.35 18 43.11 [60.08, 26.14]
ZhangW, 201355 116.51 28.74 32 153.45 29.25 32 36.94 [51.15, 22.73]
Zheng, 201256 94.33 31.58 160 109.83 35.5 160 15.50 [22.86, 8.14]
PC-III
Dai, 201114 8.8 1.2 34 10.8 2.5 34 2.00 [2.93, 1.07]
Ding, 201216 85.6 20.1 26 128 22.5 24 42.40 [54.26, 30.54]
Lang, 201325 105 53 76 186 64 76 81.00 [99.68, 62.32]
Li, 201327 104.92 53.48 33 186.39 64.33 32 81.47 [110.28, 52.66]
Lv, 201233 33.44 13.8 20 39.64 10.11 20 6.20 [13.70, 1.30]
Pei, 201235 169.3 58.3 29 193.6 47.6 29 24.30 [51.69, 3.09]
Peng, 201436 63.5 23.1 25 97.3 24.5 25 33.80 [47.00, 20.60]
Wang, 201245 7.26 3.52 30 9.26 5.19 30 2.00 [4.24, 0.24]
Xiao, 201447 132.3 76.5 30 156.2 87.6 30 23.90 [65.52, 17.72]
Yan, 201448 92.56 47.32 29 141.63 65.58 27 49.07 [79.21, 18.93]
Yuan, 201350 97.38 52.01 25 160.38 63.15 25 63.00 [95.07, 30.93]
ZhangFM, 201254 101.19 32.35 20 150.25 32.63 18 49.06 [69.75, 28.37]
ZhangW, 201355 106.27 31.73 32 151.23 35.61 32 44.96 [61.49, 28.43]
Zheng, 201256 115.47 32.26 160 131.73 29.61 160 16.26 [23.05, 9.47]
IV-C
Dai, 201114 82 11.9 34 115.9 18.3 34 33.90 [41.24, 26.56]
Lang, 201325 63 14 76 140 24 76 77.00 [83.25, 70.75]
Li, 201327 63.29 14.52 33 39.54 23.671 32 23.75 [14.17, 33.33]
Lv, 201233 85.39 20.3 20 105.49 44.75 20 20.10 [41.64, 1.44]
Pei, 201235 78.9 13.6 29 96.4 2.7 29 17.50 [22.55, 12.45]
Peng, 201436 49.5 25.2 25 69.7 30.1 25 20.20 [35.59, 4.81]
Wang, 201245 92.45 67.58 30 142.24 33.05 30 49.79 [76.71, 22.87]
Xiao, 201447 78.5 26.2 30 83.5 35.3 30 5.00 [20.73, 10.73]
Yan, 201448 47.36 22.41 29 62.38 23.19 27 15.02 [26.98, 3.06]
Yuan, 201350 118.95 36 25 170.93 64.91 25 51.98 [81.08, 22.88]
ZhangFM, 201254 67.52 25.16 20 106.24 25.56 18 38.72 [54.88, 22.56]
Zheng, 201256 80.47 27.34 160 95.19 28.44 160 14.72 [20.83, 8.61]
HA: Hyaluronic acid; LN: Laminin; PC-III: Precollagen type III; IV-C: Type IV collagen; ETV: Entecavir; CHM: Chinese herbal medicine.
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Study or Subgroup
1.1.1 DHZC+ADV vs ADV
Gui2012
Zhang2008
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.89, df = 1 (P = .35); I² = 0%
Test for overall effect: Z = 2.08 (P = .04)
1.1.2 FZHY+ADV versus ADV
LiuMD2013
Pan2009
Subtotal (95% CI)
Heterogeneity: Tau² = 138.02; Chi² = 1.50, df = 1 (P = .22); I² = 33%
Test for overall effect: Z = 7.54 (P < .00001)
Test for subgroup differences: Chi² = 17.70, df = 1 (P < .0001), I² = 94.3%
Mean
147
168.65
125.9
90.26
SD
48.7
71.38
127.9
30.12
Total
37
23
60
40
48
88
Mean
163
207.31
192.2
185.43
SD
55.7
66.17
66.1
30.26
Total
34
22
56
40
45
85
Weight
73.0%
27.0%
100.0%
21.3%
78.7%
100.0%
IV, Random, 95% CI
-16.00 [-40.43, 8.43]
-38.66 [-78.85, 1.53]
-22.11 [-42.99, -1.24]
-66.30 [-110.92, -21.68]
-95.17 [-107.45, -82.89]
-89.03 [-112.18, -65.88]
CHM + ADV ADV Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours [CHM + ADV] Favours [ADV]
Figure 4 The effect on HA of DHZC/FZHY plus ADV with ADV.
Notes: CHM, Chinese herbal medicine; ADV, adefovir dipivoxil; HA, hyaluronic acid; DHZC, Da Huang ZHe Chong pill; FZHY, Fuzheng
Huayu capsule.
Study or Subgroup
1.2.1 FZHY+ADV versus ADV
LiuMD2013
Pan2009
Subtotal (95% CI)
Heterogeneity: Tau² = 67.45; Chi² = 2.28, df = 1 (P = .13); I² = 56%
Test for overall effect: Z = 2.67 (P = .008)
1.2.2 FFBJ+ADV versus ADV
Dai2013
Hu2012
Jin2010
Wei2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.18, df = 3 (P = .98); I² = 0%
Test for overall effect: Z = 3.15 (P = .002)
Test for subgroup differences: Chi² = 0.93, df = 1 (P = .33), I² = 0%
Mean
112.9
109.23
101.1
102.37
103.24
101.1
SD
37.1
34.1
27.7
28.14
32.45
27.7
Total
40
48
88
33
25
30
22
110
Mean
142.1
122.94
112.5
113.69
118.73
112.5
SD
35.9
25.26
26.1
30.24
33.94
26.1
Total
40
45
85
33
25
30
22
110
Weight
44.1%
55.9%
100.0%
34.4%
22.1%
20.5%
22.9%
100.0%
IV, Random, 95% CI
-29.20 [-45.20, -13.20]
-13.71 [-25.86, -1.56]
-20.54 [-35.62, -5.47]
-11.40 [-24.39, 1.59]
-11.32 [-27.51, 4.87]
-15.49 [-32.29, 1.31]
-11.40 [-27.30, 4.50]
-12.22 [-19.84, -4.61]
CHM + ADV ADV Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours [CHM+ADV] Favours [ADV]
Figure 5 The effect on LN of FZHY/FFBJ plus ADV with ADV.
Notes: CHM, Chinese herbal medicine; ADV, adefovir dipivoxil; LN, laminin; FZHY, Fuzheng Huayu capsule; FFBJ, compound Biejia
Ruangan tablets.
Study or Subgroup
LiuMD2013
Pan2009
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.35, df = 1 (P = .55); I² = 0%
Test for overall effect: Z = 7.63 (P < .00001)
Mean
94.7
98.16
SD
27.8
15.47
Total
40
48
88
Mean
129.2
138.59
SD
37.5
42.21
Total
40
45
85
Weight
45.0%
55.0%
100.0%
IV, Random, 95% CI
-34.50 [-48.97, -20.03]
-40.43 [-53.52, -27.34]
-37.76 [-47.47, -28.06]
FZHY+ADV ADV Mean Difference Mean Difference
IV, Random, 95% CI
-50 -25 0 25 50
Favours [FZHY+ADV] Favours [ADV]
Figure 6 The effect on PC-III of FZHY plus ADV with ADV.
Notes: CHM, Chinese herbal medicine; ADV, adefovir dipivoxil; PC-III, precollagen type III; FZHY, Fuzheng Huayu capsule.
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Table 5 The original data and mean difference of the comparison, CHM plus ADV versus ADV, examining the effect on HA, LN,
PC-III, IV-C.
Study or Subgroup CHMþADV CHMþADV Mean difference
95%CIMean SD Total Mean SD Total
HA
Hu, 201121 81.2 13.4 35 121.23 24.41 35 40.03 [49.26, 30.80]
Li, 201226 173.52 32.51 25 227.51 59.32 23 53.99 [81.38, 26.60]
Qian, 201137 115.27 66.81 46 144.5 87.89 43 29.23 [61.83, 3.37]
Qin, 201238 138.56 48.95 30 178.61 64.41 30 40.05 [69.00, 11.10]
Si, 200940 189.4 34.5 28 281.8 16.7 30 92.40 [106.51, 78.29]
Xie, 201059 128 53 40 242 130 40 114.00 [157.51, 70.49]
Yang, 201149 142.8 43.4 33 180.8 49.7 30 38.00 [61.14, 14.86]
Zhu, 201258 138.56 48.9 30 178.62 64.41 30 40.06 [69.00, 11.12]
LN
Gui, 201219 72 25.2 37 98 27.3 34 26.00 [38.25, 13.75]
Hu, 201121 78.32 16.5 35 68.62 17.02 35 9.70 [1.85, 17.55]
Li, 201226 124.92 19.73 25 165.52 58.41 23 40.60 [65.69, 15.51]
Qian, 201137 76.56 45.58 46 106.43 67.31 43 29.87 [53.92, 5.82]
Qin, 201238 103.24 32.45 30 118.73 33.94 30 15.49 [32.29, 1.31]
Si, 200940 162.8 36.4 28 150.3 17.8 30 12.50 [2.41, 27.41]
Xie, 201059 166 34 40 228 52 40 62.00 [81.25, 42.75]
Yang, 201149 68.9 19.2 33 88.3 23.2 30 19.40 [29.98, 8.82]
Zhang, 200851 109.39 30.47 23 112.45 28.19 22 3.06 [20.20, 14.08]
Zhu201258 104.4 39.6 30 142.3 50.4 30 37.90 [60.84, 14.96]
PC-III
Dai, 201315 129.4 46.6 33 130.5 50.1 33 1.10 [24.44, 22.24]
Gui, 201219 144 23.4 37 167 27.2 34 23.00 [34.85, 11.15]
Hu, 201222 108.44 13.66 25 159.31 22.19 25 50.87 [61.08, 40.66]
Jin, 201024 104.53 32.86 30 119.79 32.86 30 15.26 [31.89, 1.37]
Li, 201226 90.11 50.13 25 182.43 59.71 23 92.32 [123.65, 60.99]
Qian, 201137 63.75 23.18 46 97.31 24.8 43 33.56 [43.55, 23.57]
Qin, 201238 104.53 32.86 30 119.79 32.86 30 15.26 [31.89, 1.37]
Si, 200940 171.2 38.2 28 192.1 37.8 30 20.90 [40.47, 1.33]
Wei, 201046 129.4 46.6 22 130.5 50.1 22 1.10 [29.69, 27.49]
Yang, 201149 142.5 25.1 33 160.7 24.8 30 18.20 [30.53, 5.87]
Zhang, 200851 109.9 13.67 23 161.68 23.23 22 51.78 [62.98, 40.58]
Zhu, 201258 90.3 46.4 30 89.2 55.6 30 1.10 [24.81, 27.01]
IV-C
Dai, 201315 98.8 24.3 33 174.9 38.6 33 76.10 [91.66, 60.54]
Hu, 201121 57.25 18.5 35 80.53 37.04 35 23.28 [37.00, 9.56]
Hu, 201222 97.96 72.49 25 126.31 60.35 25 28.35 [65.32, 8.62]
Jin, 201024 57.25 18.5 35 80.53 37.04 35 23.28 [37.00, 9.56]
Li, 201226 79.4 54.41 25 124.41 62.22 23 45.01 [78.20, 11.82]
LiuMD, 201330 77.9 34.9 40 101.9 35.9 40 24.00 [39.52, 8.48]
Pan, 200934 85.27 18.36 48 83.21 20.18 45 2.06 [5.80, 9.92]
Qian, 201137 47.45 31.12 46 69.27 30.51 43 21.82 [34.63, 9.01]
Qin, 201238 102.76 35.72 30 132.76 42.89 30 30.00 [49.97, 10.03]
Si, 200940 145.2 26.7 28 196.7 32 30 51.50 [66.63, 36.37]
Wei, 201046 98.8 24.3 22 174.9 38.6 22 76.10 [95.16, 57.04]
Xie, 201059 74 38 40 130 75 40 56.00 [82.06, 29.94]
Zhang, 200851 98.97 75.68 23 128.67 61.68 22 29.70 [69.96, 10.56]
Zhu, 201258 112.9 65.4 30 157.4 99.8 30 44.50 [87.20, 1.80]
HA: Hyaluronic acid; LN, Laminin; PC-III: Precollagen type III; IV-C: Type IV collagen; ADV: Adefovir dipivoxil; CHM: Chinese herbal
medicine.
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22 T. Li et al.1) did not report the methods of random sequence gener-
ation and allocation concealment;
2) did not report the information on withdrawal/dropout
during the trials or, if reported, the detailed reasons
were not reported;
3) did not report registration information.Comparison with previous systematic reviews
One related systematic review60 was found. Its objective
was to review the effectiveness of CHM on treating liver
fibrosis patients suffering from fatty liver, schistosomiasis
japonica, or chronic hepatitis. The measures of interven-
tion included CHM, western medicine, placebo, or no
intervention. Twenty-three RCTs were included and the
results led to the conclusion that apart from being
compared with a placebo, these therapies significantly
improved the levels of HA, LN, PC-III, and IV-C when
compared with western medicine alone, CHM alone, or CHM
plus western medicine. Compared to this study, we
included trials in which participants suffered from
compensated HBV-related cirrhosis, the intervention group
was treated by CHM plus NAs, and the control group was
treated with NAs alone. In addition to the liver fibrosis
biomarkers ALT and AST, TBiL, ALB, liver biopsy, and liver
stiffness were included in our outcomes. Finally, we found
that CHM plus NAs (LAM, ETV, ADV, or multiple NAs) could
improve the levels of HA, LN, PC-III, IV-C, ALT, AST, TBiL,
and liver stiffness; however, none of the treatments
affected ALB.
Implications for clinical practice and future studies
First, for participants with compensated HBV-related
cirrhosis, CHM as a conventional treatment combined with
NAs (LAM, ETV, ADV, or multiple NAs) appeared to be more
beneficial in controlling liver fibrosis because it changed
the result of the liver biopsy; reduced the levels of HA, LN,
PC-III, IV-C, ALT, AST, TBiL; and decreased liver stiffness;
however, ALB levels were not improved. ALB is synthesized
by liver cells and the reason that combined therapy had
little effect on ALB could be related to the number and
quality of the trials or that the differences in ALB levels
might not be obvious between the two methods. This
should be heeded in clinical practice.
Second, substantial evidence related to the quality of
life, incidence of decompensated cirrhosis or liver cancer,
or traditional Chinese medicine (TCM) syndrome were
lacking. As for TCM syndrome, the basic principle for
treating diseases in TCM is syndrome differentiation; how-
ever, only seven studies18,29,30,33,35,50,54 referred to syn-
drome differentiation among the trials included.
Third, none of the trials included could provide access to
information on their registered protocols. Thus, to retrieve
their valid conclusions, we encourage the authors to reg-
ister their study protocols before trial implementation. We
believe that future studies, especially on TCM clinical
research, should be designed based on the theory of TCM.
TCM syndrome or symptoms should be part of the out-
comes, even the primary outcomes.Conflicts of interest
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ALT Alanine aminotransferase
AST Aspartate aminotransferase
ALB Albumin
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CI Confidence interval
WMD Weighted mean difference
LAM Lamivudine
ADV Adefovir dipivoxil
ETV Entecavir
FFBJ Compound Biejia Ruangan Tablets
BSHY Bushen Huayu Decoction
HLSG Heluo Shugan Capsule
DHZC Dahuang Zhechong Pill
FFDS Compound Danshen Dripping Pills
YiGJ Yiguanjian Decoction
XiXS Xiaoxian Pulvis
FZHY Fuzheng Huayu Capsule
QiGa Qianggan Capsule
RJHY Ruanjian Huayu Decoction
GLXD Ganlu Xiaodu Pill
YQHYRJ Yiqi Huayu Ruanjian Decoction
FZRG Fuzheng Ruangan Pill
LWWL Liuwei Wuling tablets
RuGa Ruangan pill
Chinese herbal medicine combined with nucleotide 23ALHX Anluo Huaxian Pill
YQPXXQ Yiqi Poxue Xingqi Decoction
RGWJ Ruangan Wenjing Paste
HYYG Huayu Yigan Capsule
JWXY Jiawei Xiaoyao Capsule
SGJPHX Shugan Jianpi Huoxue Decoction
DaYe Danye Capsule
RGHX Ruangan Huaxian Capsule
WJBF Wuji Baifeng Wan
NR No report
Appendix A. Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jtcms.2014.12.006.References
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